Kazia Therapeutics Ltd ADR (KZIA)
Kazia Therapeutics Ltd ADR is a NASDAQ-listed depositary receipt tied to Kazia Therapeutics Limited, an oncology-focused biotechnology company headquartered in Sydney, Australia. The underlying issuer, which was incorporated in 1994 and previously operated as Novogen Limited before adopting its current name in 2017, develops cancer therapies through its subsidiaries. Its lead program is paxalisib, a brain-penetrant small-molecule inhibitor of the PI3K/AKT/mTOR pathway that is being studied in glioblastoma and several other brain-related cancers, with additional pre-clinical work in triple-negative breast cancer and atypical rhabdoid/teratoid tumors. Kazia also is advancing EVT801, a VEGFR3 inhibitor in early-stage clinical testing for advanced solid tumors and ovarian cancer. The company has research collaborations with several academic and industry partners, including Genentech, Evotec, Vivesto, Simcere, and others.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-KZIA
|
$10.97
|
-21.8% Downside
|
Overvalued
|
$27.78
|
98.0% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
September 4, 2026
|
-10.0x
|
4.9x
|
120.3x
|
154.8 M
|
108.4 M
|
0.0%
|
70.9%
|
1.0
|
—
|
63.1%
|
